[procaare] HIV drug resistance

[AIDS2002 <procaare@usa.healthnet.org>]

HIV drug resistance
***************************

"Inexperienced physicians treating patients with HIV/AIDS pose a risk factor for the
development of drug resistance," said John Mellors of the University of Pittsburgh, during
an IAS-WHO satellite meeting on HIV drug resistance on Monday.

Roberto Siliciano, in his address to the first plenary session described the mechanism by
which HIV infection persist in infected persons. When CD4 cells are infected, most die,
but many revert to a resting state, which provides a reservoir for future resurgence of
infection. With effective antiretroviral therapy (ART), the viruses in the resting memory
cells are prevented from evolving, and those that are drug-resistant in the CD4 lymphocyte
resting memory cells, will remain resistant, while those which are not resistant will also
remain so.

Viral drug resistance is one of the major topics of discussion at AIDS 2002 and at the
satellite meeting, Dr Mellors presented a scientific overview of current knowledge of drug
resistance.

He provided some key points which have been learned:
* No antiretroviral drug is resistance-proof. HIV has evolved to escape selective pressure
whether it be from drugs or the immune system
* Incomplete suppression of HIV replication leads to drug resistance. This is often
associated with incomplete adherence; multiple drug resistance is found in up to 30% of
people on HAART after two years
* Resistance can lead to disease progression and death unless the viral RNA is suppressed
to below 50 copies/mL
* Resistant viruses can spread, and can affect initial responses to therapy
* Resistance is not inevitable. Careful choice of regimens can minimise or prevent
resistance

In order to monitor drug resistance world wide the WHO is setting up a global drug
resistance surveillance network, which will provide reliable guidelines based on
geographical and temporal trends. It will monitor outcomes to determine what causes or
exacerbates, and what prevents drug resistance. Surveillance will be linked to ART
programmes.

One of the aims is standardisation of data collection. The WHO wants the surveillance
programme to be useful to all involved from government and health care providers to the
public and commercial enterprises.

Key Correspondent
Health & Development Networks

AIDS2002 Conference
Barcelona, July 7-12, 2002

Email: correspondents@hdnet.org
Web: http://www.hdnet.org

--
To send a message to ProCAARE, write to: procaare@usa.healthnet.org
To subscribe or unsubscribe, write to: majordomo@usa.healthnet.org
in the body of the message type: subscribe procaare OR unsubscribe procaare
To contact a person, send a message to: procaare-help@usa.healthnet.org
Information and archives: http://www.procaare.org

The views presented in ProCAARE do not necessarily reflect the opinions of
SATELLIFE  (http://www.healthnet.org), the Harvard AIDS Institute
(http://aids.harvard.edu), or Health & Development Networks
(http://www.hdnet.org), unless otherwise stated. The reader assumes all
responsibilities in using information posted or archived by ProCAARE.
Reproduction is welcomed, provided ProCAARE and procaare@usa.healthnet.org
are quoted, and SATELLIFE is informed of usage.